Ripretinib May Provide ‘Meaningful Clinical Benefit’ in Advanced GIST
Ripretinib did not improve progression-free survival but proved more tolerable than sunitinib.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
Risk for Cancer Increased After VTE for Patients With Psoriasis
The absolute risk for overall cancer was 4.7% during the first year of follow-up.
COVID-19 Vaccination During Chemotherapy Deemed Safe for Gastrointestinal Cancers
The study revealed no new safety signals compared with previous reports.
Opioid Use Linked to Survival in Older Patients With Advanced Pancreatic Cancer
The median survival was significantly longer in patients who received opioid prescriptions than in those who did not.
The Role of Twitter in Colorectal Cancer Awareness
The most common topics of tweets were early detection of disease, bereavement, and research.
Prophylactic Post-Surgical TACE Improves Survival in Intrahepatic Cholangiocarcinoma
There was no significant difference in survival between the TACE and non-TACE groups overall, but there were differences for prophylactic post-surgical TACE, palliative TACE, and curative TACE.
Oxaliplatin Does Not Benefit Older Patients With Metastatic Colorectal Cancer
Oxaliplatin did not prolong progression-free survival and was associated with more adverse events.
Elevated Platelet Count Could Be a Biomarker for Several Cancers
Compared with patients who had a medium platelet count, patients with a very high platelet count had more than double the risk of a solid tumor diagnosis.
Stopping Adjuvant Treatment Early May Decrease DFS, OS in Stage III Colon Cancer
Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.
First Positive First-Line Immuno-Chemotherapy Results for Biliary Tract Cancer
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
Eryaspase Does Not Improve PFS or OS in Advanced Pancreatic Cancer
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
STRIDE Regimen Extends Survival in Unresectable Hepatocellular Carcinoma
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE Improves Efficacy of Lenvatinib in Advanced Hepatocellular Carcinoma
TACE improved responses and survival outcomes.
COVID-19 Pandemic Did Not Affect Care of Pancreatic Cancer Patients
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
Sintilimab Improves Response to Chemotherapy in Advanced Pancreatic Cancer
The improvement in response did not translate to a survival benefit.
Adjuvant S-1 Improves OS, Is Labelled New Standard in Biliary Tract Cancer
Adjuvant S-1 improved survival over surgery alone.
Outcomes Similar With Etoposide or Irinotecan Plus Cisplatin in Gastrointestinal Neuroendocrine Carcinoma
Both platinum-based chemotherapy regimens are standard of care for digestive system neuroendocrine carcinoma.
Neoadjuvant DCF Dubbed New Standard Care for Locally Advanced Esophageal Cancer
Adding docetaxel to cisplatin and fluorouracil improved overall survival.
Trastuzumab Deruxtecan Improved OS, ORR in HER2+ Gastric/GEJ Adenocarcinoma
The updated results are from a median survival follow-up of 18.5 months and 133 overall survival events.
Could Immunotherapy Delay, Eliminate Surgery in Gastric/GEJ Cancer?
About 59% of patients achieved a pathologic complete response.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Expertscape
Loading... 
Loading...